Compare KNF & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNF | ICUI |
|---|---|---|
| Founded | 1917 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.2B |
| IPO Year | N/A | 1992 |
| Metric | KNF | ICUI |
|---|---|---|
| Price | $76.29 | $147.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $96.43 | ★ $183.60 |
| AVG Volume (30 Days) | ★ 462.1K | 236.9K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $3,048,164,000.00 | $2,320,363,000.00 |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $5.46 | N/A |
| P/E Ratio | $29.60 | ★ N/A |
| Revenue Growth | ★ 5.52 | N/A |
| 52 Week Low | $58.72 | $107.00 |
| 52 Week High | $108.83 | $175.51 |
| Indicator | KNF | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 60.00 | 62.94 |
| Support Level | $73.68 | $141.10 |
| Resistance Level | $79.11 | $148.95 |
| Average True Range (ATR) | 2.03 | 3.94 |
| MACD | 0.22 | -0.36 |
| Stochastic Oscillator | 61.63 | 57.94 |
Knife River Holding Co is an aggregates-led construction materials and contracting services provider. Its segments include Pacific, Northwest, Mountain, North Central, South, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.